Abstract | The coordinated expression and activity of the iodothyronine deiodinases regulate thyroid hormone levels in hypothyroidism. Once heralded as the pathway underpinning adequate thyroid-hormone replacement therapy with levothyroxine, the role of these enzymes has come into question as they have been implicated in both an inability to normalize serum levels of tri-iodothyronine (T 3 ) and the incomplete resolution of hypothyroid symptoms. These observations, some of which were validated in animal models of levothyroxine monotherapy, challenge the paradigm that tissue levels of T 3 and thyroid-hormone signalling can be fully restored by administration of levothyroxine alone. The low serum levels of T 3 observed among patients receiving levothyroxine monotherapy occur as a consequence of type 2 iodothyronine deiodinase (DIO2) in the hypothalamus being fairly insensitive to ubiquitination. In addition, residual symptoms of hypothyroidism have been linked to a prevalent polymorphism in the DIO2 gene that might be a risk factor for neurodegenerative disease. Here, we discuss how these novel findings underscore the clinical importance of iodothyronine deiodinases in hypothyroidism and how an improved understanding of these enzymes might translate to therapeutic advances in the care of millions of patients with this condition.
Introduction
Thyroid hormones are iodinated molecules produced by the thyroid gland that regulate development, growth, energy homeostasis, cardiovascular systems, musculo skeletal systems and cognitive function. Insufficient levels of the thyroid hormones tetraiodothyronine (T 4 ) and triiodothyronine (T 3 ) result in hypothyroidism, a prevalent condition that affects more than 8 million patients in the USA alone 1 and 1-2% of individuals living in iodinereplete communities. 2 Over the past 150 years, treatment modalities for hypo thyroidism have been developed around thyroid hormone 'replacement' through administration of thyroid gland extracts, 3 which remained the mainstay of therapy for nearly a century. However, with the discovery in 1970 that, in humans, iodothyronine deiodinases produce most of the circulating T 3 , 4 clinical standards abruptly shifted to align with the assumption that levo thyroxine mono therapy would maintain the pool of T 4 and that a group of enzymes known as the iodothyronine deiodinases would provide physiologic regulation of the T 3 availability to tissues. 5 For the past few decades, clinicians have displayed an almost dogmatic reliance upon the ability of the iodo thyronine deiodinases to mediate conversion of T 4 to T 3 and thereby regulate the availability of serum levels of T 3 among patients with hypothyroidism who are treated with levothyroxine. 6 However, we now understand that ~12% of all patients treated with levothyroxine are bio chemically euthyroid (that is, they have normal serum levels of TSH) but continue to experience residual symptoms of hypo thyroidism, including psycho logical [7] [8] [9] and metabolic effects. 10, 11 This finding represents a major publichealth concern given the high prevalence of hypothyroidism and the fact that not all parameters are restored by levo thyroxine monotherapy. With such strong reliance on the iodothyronine deiodinases and, therefore, the efficacy of levothyroxine monotherapy, clinicians were left with few options to explain or treat these residual symptoms.
As awareness of this subpopulation of patients with hypothyroidism has improved, investigators have made advances in understanding the aetiology of this phenom enon. Serum levels of T 3 might not be fully normalized among such patients owing to insufficient T 4 toT 3 con version, 12 which could explain why a minority remain symptomatic despite treatment with levothyroxine. Some patients demonstrate improved wellbeing and a treat ment preference when coadministered levo thyroxine and liothyronine; 13, 14 however, this issue has remained contentious as the majority of clinical trials have failed to demonstrate an objective benefit of combination therapy. 15, 16 Differences within subgroups of patients with hypo thyroidism could make them more or less responsive to levothyroxine monotherapy versus combination therapy. 13 Therefore, the iodothyronine deiodinases that were once almost universally accepted as the key clinical strategy to thyroidhormone regulation in hypothyroid ism might actually cause continued symptoms among a substantial proportion of patients.
Here, we review the physiologic role of the iodo thyronine deiodinases, as well as the changes that occur in hypothyroidism, with particular focus on their role in preserving thyroid hormone levels in the brain. The latest studies indicate that unique biochemical aspects of the iodothyronine deiodinases in the hypothalamus prevent normalization of serum levels of T 3 in patients treated with levothyroxine monotherapy. In combination with a preva lent DIO2 polymorphism, this finding could also explain the insufficient symptomatic response experi enced by an appreciable proportion of patients with hypothyroidism.
Animal models of thyroid replacement
Further insight into the regulation of iodothyronine deiodin ases and tissuespecific thyroidhormone signal ling is required to develop new strategies to treat hypo thyroidism. However, studies in humans are limited as they require tissue biopsy samples. Thus, animal models have been developed that provide the basis for how unique aspects of iodothyronine deiodinase regulation might affect different thyroidhormone replacement therapies. [17] [18] [19] [20] The applicability of such models reflects the exten sive similarities in thyroid physiology between humans and small rodents. 21 Interspecies differences exist but their interference can be minimized by correct experi mental planning. For example, the halflives of T 4 and T 3 are longer in humans (~1 week and 1 day, respectively) than in rodents (~8 h and 2 h, respectively) and so blood and/or tissue sampling should be planned accordingly. 21 Iodothyronine deiodinases are conserved across species at the amino acid level but they have speciesspecific differences in tissue distribution. Type 2 iodothyronine deiodin ase (DIO2) is expressed in the human thyroid gland and heart but not in these tissues in rodents. 22, 23 Furthermore, DIO2 is the only activating iodothyronine deiodinase in the human brain, whereas both Dio2 and type 1 iodothyronine deiodinase (Dio1) are expressed in the rat brain. 24, 25 With these differences in mind, studies in thyroidec tomized rats have conclusively shown that only therapy with a combination of levothyroxine and liothyro nine Key points ■ Levothyroxine monotherapy at doses that normalize serum levels of TSH does not universally restore parameters of thyroid hormone levels for patients with hypothyroidism ■ The iodothyronine deiodinases provide a cell-specific, prereceptor mechanism that controls thyroid-hormone signalling ■ Localized thyroid-hormone signalling has a critical role in different areas of the brain, as mediated by thyroid hormone transporters and the iodothyronine deiodinases ■ DIO2 ubiquitination induced by tetraiodothyronine (T 4 ) normally decreases tri-iodothyronine (T 3 ) production, but not in the hypothalamus ■ The levothyroxine dose that normalizes serum levels of TSH in an animal model is lower than the dose that normalizes serum levels of T 3 , which explains the increased serum T 4 to T 3 ratio observed in patients treated with levothyroxine ■ If patients carrying the Thr92AlaD2 polymorphism derive benefit from combination therapy with levothyroxine and liothyronine, then genotyping for this single nucleotide polymorphism might become a component of the management of hypothyroidism could normalize serum and tissue levels of T 3 . 18, 19 Similar conclusions were obtained for normalization of T 3 dependent biological parameters, such as lipid profile, mitochondrial content and the expression of T 3 target genes, in the brains of thyroidectomized rats. 17 Mouse models were also instrumental in the discovery that preserving the stability of serum concentrations of T 3 is a biological priority, which is enforced even when Dio1 and/or Dio2 are genetically inactivated in all tissues 26 or in specific tissues. 27, 28 Therefore, animal models have provided substantial advances in our understanding of thyroidhormone replacement therapy.
Thyroid-hormone signalling
In humans, thyroid hormones are secreted into the circula tion predominantly as a prohormone (T 4 ), and only ~20% is secreted as the biologically active T 3 form. T 4 and T 3 enter almost all cells through transporters in the plasma mem brane and remain in equilibrium between plasma and cells ( Figure 1 ). Once inside a cell, T 3 diffuses into the nucleus and binds to a thyroidhormone receptor (either TRα or TRβ) to modulate gene expression. The T 3 -TR complex controls expression of specific sets of genes that are respon sive to T 3 , thus promoting T 3 dependent biological effects. Tissues contain different combinations of TRα and/or TRβ as well as other transcriptional coregulators of the T 3 -TR complex. The net effect of T 3 , therefore, depends on these combinations and is highly cell and/or tissuespecific. 29, 30 Studies in patients, animal models and in vitro cell models with mutations in the genes encoding TRα or TRβ have highlighted the mechanisms involved in the positive stimulation of gene transcription by T 3 . 29 Given the free T 3 concentration in the plasma (about 5 × 10 -12 M) and the affinity of TRs for T 3 (about 1 × 10 9 l/mol), the ratio of occupied to un occupied TRs is 1:1 in most tissues. Even when un occupied, TRs are predominantly bound to spe cific cisacting elements in T 3 responsive genes, such as ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2) and myelin basic protein (MBP). Unoccupied TRs have a high affinity for negative co regulators of transcription (also known as co repressors), which actively inhibits gene expression. Upon binding to T 3 , TRs lose their affinity for co repressors and gain affinity for co activators, which triggers transcriptional activa tion of T 3 dependent genes. Therefore, the clinical syn drome of an individual with hypothyroidism is largely the result of transcriptional repression of T 3 responsive genes mediated by unoccupied TRs. The goal of thyroid hormone replacement therapy is to provide sufficient T 3 to relieve TRmediated gene repression and to promote T 3 dependent transactivation of target genes. 29 The unique role of the unoccupied TRs is further illustrated by the fact that mice with a knockout for the genes encoding TRα and TRβ exhibit only a mild phenotype, mainly because no transcriptional repression occurs. 29 Therefore, the inten sity of thyroidhormone signalling depends on the ratio between occupied and unoccupied TRs, which is a func tion of the plasma T 3 concentration, presence of plasma membrane transporters, iodothyronine deiodinase activity and (ultimately) the nuclear concentration of T 3 .
Iodothyronine deiodinases
Iodothyronine deiodinases are small, highly homol o gous, integral membrane enzymes that modify thyroid hormone signalling. They comprise a single Nterminal, transmembrane segment connected to a larger globular cytosolic domain with a selenocysteinecontaining active centre embedded in a thioredoxinlike fold. The molecular structure has been modelled using hydro phobic cluster analysis 31 and confirmed with supportive experimen tal data in the case of type 3 iodothyronine deiodinase (DIO3). 32 The selenium in the active centre provides enhanced substrate affinity and a fast turnover rate for the deiodination reaction.
Both T 4 and T 3 can be deiodinated, a process that results in either activation of T 4 (by DIO1 and DIO2) or inacti vation of T 4 and T 3 (by DIO3). Consequently, the intra cellular environment can be enriched with additional T 3 supplied by DIO2 (enhancing thyroidhormone action) or depletion of thyroid hormones by DIO3 (dampening thyroidhormone action; Figure 1) . A key property of iodothyronine deiodinases in thyroidhormone signalling is their unique subcellular localization. DIO2 is usually retained in the endoplasmic reticulum; 33, 34 however, it is also closely associated with the cell nucleus, 35 but not with the Golgi apparatus. 33 As a result, the nuclear environment can be greatly affected by DIO2generated T 3 owing to this physical proximity. By contrast, DIO1 is located in the plasma membrane; it has low affinity for T 4 and so DIO1generated T 3 rapidly diffuses from the cells and reaches the plasma without appreciably affecting nuclear concentrations of T 3 . 34, 36 DIO3 is generally anchored in the plasma membrane, where it is internalized to become part of vesicles known as early endosomes that can be recycled back to the plasma membrane. 34, 37 In the rat central nervous system, Dio3 is observed in densecore vesicles of hypothalamic neuro secretory axon varicosities with the active centre contain ing the Cterminus of Dio3 at the outer surface of these organelles. 38 However, this peripheral distri bution of Dio3 can change depending on oxygen availability. For example, after unilateral induction of ischaemia and hypoxia in the rat brain, Dio3 is found predominantly in the nucleus of the neurons in the pyramidal and granular ipsilateral layers, as well as in the hilus of the dentate gyrus of the hippocampal formation. 39 In isolated mouse hippocampal neurons grown in culture and in a human neuroblastoma cell line, hypoxia redirects active DIO3 to the nucleus via the HSP40 pathway, a shuttle mechanism known to direct proteins to the nucleus. In the human neuroblastoma cell line, preventing nuclear DIO3 import by HSP40 knock down almost doubles the thyroidhormone dependent glycolytic rate and quad ruples the transcription of thyroid hormone target gene ENPP2. By contrast, over expression of HSP40 increases nuclear import of DIO3 and minimizes the effects of thyroid hormones in cell metabolism. 39 Rerouting DIO3 to the nucleus decreases thyroidhormone signalling and might function to reduce ischaemiainduced hypoxic brain damage.
The corollary to these findings is that the activity of DIO2 and DIO3 are viewed as a cellspecific, prerecep tor mechanism that controls thyroidhormone signalling, the intensity of which cannot be predicted on the basis of circulating levels of T 3 . 40 For example, cold and/or sympathetic nervous system stimulation of Dio2 expres sion in rat brown adipose tissue accelerates transcrip tion of T 3 responsive genes, such as Ucp1 and Pgc1α. 41 Furthermore, ectopic expression of DIO3 in the human Figure 1 | Iodothyronine deiodinases modulate thyroid-hormone signalling in T 3 target cells. T 4 and T 3 enter almost all cells via membrane transporters and are then modified in a cell-specific manner by DIOs to either enhance (DIO2) or diminish (DIO3) thyroid-hormone signalling. Consequently, the flow of T 3 diffusing from the cell membrane to the nucleus is increased by T 3 (T 4 ), which represents T 3 generated locally from T 4 via DIO2. By contrast, the DIO3 pathway decreases the flow of T 3 to the nucleus by terminally inactivating T 3 to T 2 and T 4 to rT 3 (rT 3 ,T 2 ). DIO2 generates T 3 in a cell compartment adjacent to the nucleus. By contrast, DIO3 largely resides in the periphery of the cell in the plasma membrane and early endosomes. Once inside cells, T 3 can diffuse to the nucleus to modulate gene expression. Abbreviations: DIO, iodothyronine deiodinase; rT 3 , reverse triiodothyronine; T 2 , di-iodothyronine; T 3 , tri-iodothyronine; T 4 , tetra-iodothyronine. Courtesy of BiancoLab.org. Nature Reviews | Endocrinology REVIEWS heart and brain during ischaemia or hypoxia 42 decreases the amount of T 3 dependent transcription in these organs, curbing thyroidhormone signalling. 43, 44 Although no humans have been identified with lossoffunction muta tions in the iodothyronine deiodinases, 45 a few indivi duals have been identified with defects in selenoprotein synthesis that results in a reduction in DIO2 activity and possible reduction in the activities of DIO1 and DIO3. These patients exhibit increased serum levels of TSH, increased serum levels of T 4 and low serum levels of T 3 , but otherwise have a mild phenotype. 46 
Effects on brain function
The fundamental impact of thyroid hormones on brain function was established by the striking link between untreated congenital hypothyroidism and developmen tal retardation of cognitive function. [47] [48] [49] Myelination, neuronal and/or glial proliferation, differentiation and neuronal migration represent crucial targets of thyroid hormonemediated events in the brain. 48, 50, 51 Access of thyroid hormones to the brain is selective, with T 4 in plasma having greater ease of access than T 3 in plasma because of the types of transporters expressed in the blood-brain barrier. 52, 53 Uptake of thyroid hormones via the blood-brain barrier and into cells inside the brain parenchyma is mediated by transporters, including monocarboxy late transporter 8 (MCT8) and solute carrier organic anion transporter family member 1C1 (SLCO1C1, also known as OATP1C1). [54] [55] [56] These transporters are plasma membrane proteins with multiple membranespanning domains that have a halflife of several days. Although levels of Mct8 and Slco1c1 mRNA are decreased in a rodent model of nonthyroidal illness, 57 currently no direct evidence exists that quick, adaptive changes in the transport of thyroid hormones regulate thyroid hormone availability in the brain. However, the observation that patients with Allan-Herndon-Dudley syndrome express a mutant MCT8 protein explained the molecular back ground of this rare Xlinked disorder, which is charac terized by neurological abnormalities (central hypotonia, hearing problems, rotatory nystagmus and spasticity) and developmental delay. 58, 59 The link between mutations in the genes that encode thyroid hormone transporters and neurological symp toms highlights the critical importance of localized thyroidhormone signalling in different areas of the brain. In contrast to the majority of tissues, a large portion of T 3 in the rodent brain is produced locally via activation of T 4 . A duallabelling approach was used to assess this process directly 60 and the findings were later confirmed in Dio2 knockout mice that exhibited ~50% reductions in levels of T 3 in the brain. 61 Thus, local metabolism of thyroid hormones (that is, via the DIO2 and DIO3 path ways) is currently viewed as the major factor that regu lates the intensity of thyroidhormone signalling in the brain. Both enzymes exhibit homeo static regulation in response to changes in serum levels of thyroid hor mones. The activity of DIO2 increases but that of DIO3 decreases in the presence of low concen trations of thyroid hormones (for example, in conditions of hypothyroidism or iodine deficiency), a finding that has been interpreted largely as a mechanism that delays adverse effects of hypothyroidism in the brain. 62, 63 Neurons are critically important targets of T 3 ; however, these cells lack DIO2 and are unable to generate T 3 via this pathway. [64] [65] [66] Indeed, enrichment of Dio2 expres sion is detected in glial cells when examining the tran scriptome of astrocytes, neurons and oligodendrocytes. 67 Furthermore, a >95% drop in Dio2 mRNA and activity occurred in the brain of a mouse model with a transgene conferring gliaspecific inactivation of this enzyme. 28 Thus, the current paradigm predicts that T 3 generated by DIO2 located in astrocytes acts in a paracrine fashion to stimulate TRs in neurons. [68] [69] [70] This hypothesis has been modelled and validated in vitro by coculturing human DIO2expressing glioma cells with human neuronal cells that express DIO3. 70 In such a system, T 3 generated by glial cells (via DIO2 activity) has a paracrine effect on the cocultured neurons and activates T 3 regulated neuronal genes. Such pathways might also affect thyroidhormone signalling in vivo. For example, DIO3 is activated by hypoxia inducible factor 1α under conditions of ischae mia and/or hypoxia. 43 Furthermore, DIO2 activity is downregulated and DIO3 expression is activated by the morphogenic hedgehog protein family. 71, 72 Logically, in responding to ischaemia or hypoxia and other cues known to regulate these enzymes, iodothyro nine deiodinases enhance or dampen thyroidhormone signalling in discrete groups of cells or areas of the brain with clear consequences. For example, in rodent models, Dio2 is involved in the generation of Tshreleasing hormone (Trh) and/or Tsh feedback ( Figure 2 ). DIO2 is also implicated in the hypothalamic regulation of non thyroidal illness, seasonal breeding in birds and the onset of hearing in rodents. [73] [74] [75] [76] Direct evidence suggests that iodothyronine deiodinases have similar roles in humans. For example, in the human fetal hypothalamus, a develop mental dependency and coordinated expression of DIO2 and DIO3 occurs in combination with the various thyroidhormone transporters. 77 In the rodent and avian retina, Dio3 dampens the actions of thyroid hormones, limiting T 3 exposure to the cone cells and preserving survival and/or patterning of opsins, which is required for cone function. 78 Some evidence supports a role for iodothyronine deiodinase mediated thyroidhormone signalling in the human brain. For example, a correlation exists between the levels of thyroid hormones and enzyme activity in dif ferent areas of the developing human brain. 79 During recovery from intraventricular haemorrhage in preterm infants, which depends on maturation of oligodendro cytes and myelination, DIO2 expression is decreased and DIO3 expression increased, which is indicative of local ized hypothyroidism. 80 Reversing this effect with levo thyroxine treatment promotes neurological recovery in infants and in a model of intraventricular haemorrhage in rabbits and, if confirmed, this approach could improve the neurodevelopmental outcome of preterm infants with intraventricular haemorrhage. 80 
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What changes in hypothyroidism?
The amount of thyroid hormone entering a cell is equiva lent to the amount exiting that cell, characterizing a state of equilibrium. Studies in animal models and human cells grown in culture suggest that the net flow of T 4 and T 3 depends on the type of iodothyronine deiodin ase expressed in each given cell type (Figure 1 ). The expression of DIO2 creates an inward net flow of T 4 and an outward net flow of T 3 . 40 Expression of DIO3 creates inward net flows of both T 4 and T 3 , whereas the net flow is neutral if no iodothyronine deiodinase is expressed. 40 Iodothyronine deiodinase activity also affects circulat ing levels of T 4 and T 3 . In humans, ~70% of the circulating T 3 is produced via the extrathyroidal DIO2 pathway, whereas ~15% originates from the DIO1 pathway. Given that DIO1 is positively regulated by T 3 , 81 whereas the opposite is seen for DIO2, the contribution of DIO1 to the circulating T 3 pool is increased in patients with hyper thyroid ism. Notably, DIO1 activity is inhibited by propylthiouracil, glucocorticoids and β blockers, which explains at least part of the clinical efficacy of these drugs. 40 Most circulating T 3 is metabolized via the DIO3 pathway. 82 This pathway acquires particular clinical rele vance during pregnancy because DIO3 is highly expressed in the human placenta, 83 and, therefore, increases the daily requirements for thyroid hormone for patients on thyroid hormone replacement therapy. 84 Increased expression of DIO3 is also observed in some disease states, including in the liver, lungs, heart and brain of patients experiencing ischaemia or hypoxia. 42 In rare cases, DIO3 is expressed in infantile haemangioma to such an extent that it inacti vates T 3 at a faster rate than the hormone can be produced (consumptive hypothyroidism). 85 Similarly, treatment of patients who have cancer with the tyrosine kinase inhib itors imatinib and sunitinib is associated with the develop ment of hypothyroidism, which seems to be the result of marked overexpression of DIO3 within the tumour cells. 86 Hypothyroidism is an important example of the mass effect of the iodothyronine deiodinases changing their levels of activity in a coordinated fashion. As a result of low thyroid hormone levels, the activity of DIO2 is accelerated in almost all tissues, increasing the wholebody fractional conversion of T 4 to T 3 that helps preserve serum levels of T 3 (the opposite is observed during hyper thyroidism). 87 In addition, DIO3 is a T 3 responsive gene and thus T 3 clearance is reduced in hypothyroidism. These coordi nated and reciprocal enzyme responses explain why meas uring serum concentrations of T 3 is of little diagnostic value in patients with hypothyroidism.
The DIO2adaptive response to hypothyroidism is pos sible because of the unique sensitivity of this enzyme to T 4 , its natural substrate. DIO2 has a short halflife (~60 min) that becomes even shorter (20 min) as a result of interact ing with T 4 and/or its catalytic activity. 88, 89 In other words, by converting T 4 to T 3 , DIO2 is inactivated and degraded. This mechanism is explained by an 18amino acid instabil ity loop unique to the DIO2 protein that is located adja cent to its globular catalytic domain. 71 This loop mediates binding to the hedgehoginducible protein WD repeat and SOCS boxcontaining protein 1 (WSB1), a ubiquitin ligase adaptor that mediates DIO2 ubiquitination and tar geting for proteasomal degradation. 90 Truncation analyses identified a core of six amino acids within the loop as the minimal requirements critical for recognition of DIO2 by Figure 2 | T 4 -induced DIO2 ubiquitination in thyroid hormone homeostasis. In response to thyroid hormone signals from the periphery and DIO2-expressing tanycytes, hypophysiotropic TRH-expressing neurons release TRH into the portal blood. TRH is transported to the anterior pituitary gland where TSH is secreted and stimulates the thyroid gland to produce and secrete T 4 and T 3 . Hypothalamic T 3 is generated locally by tanycytes and enters the systemic circulation. T 3 can also be generated in the periphery via DIO1. In most peripheral tissues, exposure to T 4 accelerates inactivation of DIO2 (UbDIO2) and UbDIO2 targeting to the proteasomal system; however, UbDIO2 can be reactivated and rescued fromproteasomal destruction by deubiquitination. Peripheral deiodination is very sensitive to T 4 -induced DIO2 ubiquitination: a mild increase in the serum T 4 :T 3 ratio favours DIO2 inactivation and decreases fractional T 4 -to-T 3 conversion and peripheral T 3 production. However in the hypothalamus, DIO2 is less susceptible to T 4 -induced ubiquitination than in other tissues. Thus, T 4 signalling via DIO2-mediated T 3 production is very effective in the hypothalamus, whereas T 3 production via DIO2 is easily inhibited in the periphery. Abbreviations: DIO, iodothyronine deiodinase; T 2 , di-iodothyronine; T 3 , tri-iodothyronine; T 4 , tetra-iodothyronine; TRH, TSH-releasing hormone; UbDIO2, ubiquitinated DIO2. 
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WSB1. 91 The loop explains the short halflife of DIO2, a characteristic that can be transferred between proteins if the loop is fused to an otherwise stable protein. 33 As with the other iodothyronine deiodinases, DIO2 exists as a dimer that is maintained by interacting sur faces within its transmembrane and globular cytosolic domains. 92 Upon binding T 4 , DIO2 is ubiquitinated with ubiquitin chains formed at the Lys48 position, 93 which in turn inactivates the enzyme by interfering with globular interacting surfaces critical for dimerization and cata lytic activity. 90 This inactive state can be transient or per manent, depending on whether ubiquitinated DIO2 is reacti vated by DIO2interacting deubiquitinases (such as ubiquitin specific peptidase 33), 94 or retrotranslocated to the cytoplasm via the p97-ATPase complex and deliv ered to the proteasomes. 93 The continuous association of DIO2 with this regulatory protein complex supports rapid cycles of deiodination, conjugation to ubiquitin and enzyme reactivation by deubiquitination, which enables tight control of thyroidhormone action (Figure 2 ).
Treatment of hypothyroidism
Limitations of levothyroxine monotherapy Unique aspects of hypothalamic DIO2 define limita tions of levothyroxine replacement therapy and the use of TSH as a therapeutic goal. Circulating T 4 and T 3 exert negative feedback on the secretion of TRH and TSH. 76 In rodents, Tshsecreting cells coexpress Dio2; 95 in the rodent hypothalamus, Dio2 is expressed in specialized glial cells known as tanycytes (Figure 2 ). These cells are located in the mediobasal hypothalamus, as well as on the floor and infralateral wall of the third ventricle. Tanycytes are distributed from the end of the optic chiasm, along the mammillary recess, and their processes also reach the median eminence outside the blood-brain barrier. 64, 65, 76 The presence of DIO2 in both locations is critical for T 4 mediated negative feedback. 28, 96 In the pituitary gland, T 4 must be converted to T 3 to suppress secretion of TSH. In the hypothalamus, T 3 generation via DIO2 in tany cytes is likely to negatively affect TRH expression in the paraventricular nucleus. 97 However, the full extent of the function of DIO2 at both sites is only just starting to be appreciated. 17 Given that DIO2 activity is increased in most tissues during hypothyroidism and decreased in hyperthyroidism (via ubiquitination), its presence in the mediobasal hypothalamus and thyrotropic cells would seem to be counter produc tive to the feedback mechanism. Thus, for many years it remained unclear how fluctuations in plasma levels of T 4 could be faithfully transduced in the nuclei of thyrotropic cells and hypophysiotropic TRH neurons in the hypothalamic paraventricular nucleus to ultimately regulate serum concentrations of TSH. 95 The key new element in this feedback mechanism is the observation that rat hypothalamic Dio2 is stable and largely refractory to the levels of thyroid hormones. 17 In contrast to the rest of the body, DIO2mediated T 4 toT 3 conversion in the hypothalamus is not accelerated during hypothyroidism nor is it diminished by hyperthyroidism or administration of thyroid hormones. Indeed, a sensitiv ity gradient exists in the DIO2 response to hypothyroidism and thyroid hormones between the hypothalamus and the rest of the brain and body, 17 which is similar to previous observations in rodent thyrotropic cells. 95 The corollary of these experiments is that the secretion of Trh and Tsh in rodents is controlled by a steady process of Dio2mediated T 4 toT 3 conversion, thus transducing minor changes in serum levels of T 4 ( Figure 2 ). By contrast, the rate of Dio2mediated T 4 toT 3 conversion in the rest of the body progressively decreases with administration of thyroid hor mones because of Dio2 ubiquitination, so that peripheral T 3 production in levothyroxinetreated hypothyroid rats is progressively decreased and selflimiting. As a result, the dose of levothyroxine required to normalize serum con centrations of TSH is lower than the dose that normalizes serum levels of T 3 . Given that the rat model reproduces the findings observed among patients treated with levothyrox ine, similar pathways in humans are expected to provide the mechanistic basis for the observation of an increased ratio of serum T 4 to T 3 in the setting of normalized serum levels of TSH that is frequently observed among patients treated with levothyroxine. 12 Differences in hypothalamic DIO2 susceptibility to ubiquitination explain localized sensitivity to levo thyroxine. 17 Both in vivo studies in mice harbouring astrocytespecific inactivation of Wsb1 and in vitro ana lysis of DIO2 ubiquitination induced by different tissue extracts indicated that DIO2 ubiquitination in the hypo thalamus is lower or that deubiquitination is faster than in other tissues. 17 As a result, in contrast to other DIO2 expressing tissues, the hypothalamus is wired to have increased sensitivity to T 4 .
Hypothalamic DIO2 is also sensitive to other stimuli that are involved in the hypothalamic-pituitary-thyroid axis, including nutritional and inflammatory signals. 76 The regulation of DIO2 activity in tanycytes, therefore, also integrates other signals that override the input provided by circulating levels of thyroid hormone. For example, in a rodent model of lipopolysaccharideinduced nonthyroidal illness, Dio2 is upregulated in tanycytes, which results in increased local thyroidhormone signalling that in turn suppresses TRH expression despite falling serum levels of thyroid hormone. 98, 99 Notably, lipopolysaccharide mediated downregulation of Trh does not occur in mice with global inactivation of Dio2, which indicates that this pathway is required for this process. 70 Studies in transgenic mice suggest that mice without appreci able Dio2 expression in astrocytes, but with an intact tanycyte Dio2 pathway, can efficiently regulate their hypothalamic-pituitary-thyroid axis. 28 Normalization of T 3 levels in hypothyroidism Many patients receiving levothyroxine do not achieve serum levels of T 3 within the normal range and have raised serum levels of T 4 , which results in a high serum T 4 :T 3 ratio. 12, 100, 101 Although this phenomenon has been recognized for many decades, clinicians generally adopted the hypothesis that iodothyronine deiodin ases would appropriately regulate the pool of available T 3 at the cellular and tissue level, thus leaving patients treated with levothyroxine euthyroid. However, some investigators have questioned whether a low serum level of T 3 and/or a high T 4 :T 3 ratio could have clinical impli cations. Specifically, whether this situation causes the residual symptoms experienced by a minority of patients treated with levothyroxine. 9, 102 The clinical data remain contentious. 15, 18, 19 However, studies in rats indicate that levothyroxine administration alone does not normalize serum Tsh, serum T 3 and tissue T 3 levels at the same time, 18 and that a serum Tsh level within the normal range coexists with reduced serum and tissue T 3 levels. These issues have been confirmed in an animal study in which thyroidectomized rats receiving levothyroxine monotherapy exhibited low levels of serum T 3 and a high T 4 :T 3 ratio. 17 The novelty of this study was not only that these abnormalities in systemic parameters were confirmed but also that tissuespecific markers of hypothyroidism were evaluated. Mitochondrial content and αglycerophosphate dehydrogenase activity-both known markers of T 3 responsiveness in the liver and skeletal muscle-were normalized in rats receiving levo thyroxine plus liothyronine combination therapy but not in those treated with levothyroxine alone. 17 In addi tion, serum levels of cholesterol were normalized in rats receiving combination therapy but not in those receiving levothyroxine monotherapy.
Therefore, in the rodent model, levothyroxine replace ment therapy that results in a high ratio of T 4 to T 3 and low serum levels of T 3 seem to exert consequences on markers of hypothyroidism at the tissue level (liver and skeletal muscle). The application of these findings to human studies will be important to determine whether patients treated with levothyroxine experience tissue specific hypothyroidism and, if so, whether this effect can be reversed with combination therapy.
Thyroid-hormone homeostasis in the brain
The plasma contributes approximately half of the T 3 present in the rodent brain, with the remainder pro duced locally via deiodination of T 4 ; 61 therefore, a drop in serum levels of T 4 or T 3 could negatively affect thyroid hormone signalling in the brain. However, this effect is largely minimized by the homeostatic actions of the iodo thyronine deiodinases. 63 Accordingly, normalization of T 3 levels in the cerebral cortex, but not in the cerebellum, in levothyroxine treated thyroidectomized rats is achieved when circulating levels of T 4 and T 3 are half that of euthy roid control animals that did not undergo thyroidectomy. 18 In addition, levels of T 3 in the cerebral cortex remain within the normal range, despite an up to 20fold increase in the levothyroxine infusion doses.
These landmark studies provide the rationale for very tight control of thyroid hormone actions in the brain. These findings suggest that thyroidhormone signalling is preserved in the brains of patients with mild hypo thyroidism. However, the different behaviour of rat cere bral cortex and cerebellum confirm that thyroidhormone signalling in the brain is highly compartmentalized (that is, not all brain areas behave in the same way). To address this issue, the action of thyroid hormone was studied using 16 genetic markers (such as ENPP2) of T 3 responsiveness in the cerebral cortex, cerebellum and hippocampus of thyroidectomized rats treated with either levothyroxine monotherapy or levothyroxine plus liothyronine combina tion therapy at doses that normalize serum levels of Tsh. 17 Expression of all genetic markers returned to normal levels in thyroidectomized rats receiving combination therapy, whereas 10 markers failed to be normalized in those receiving monotherapy, which is indicative of cerebral hypothyroidism. 17 The animals receiving monotherapy had reduced serum levels of T 3 , which might explain some of these observations. An additional explanation is that the reduction of Dio2 activity in the brain observed in levothyroxinetreated animals (caused by the raised serum T 4 :T 3 ratio) could lead to decreased T 3 production via Dio2 and add to the localized hypothyroidism. 17 These findings challenge the idea that the impact of reduced DIO2 activity on T 3 production following expo sure to T 4 is compensated for by increased substrate availability, thus preserving or even increasing T 3 pro duction. Although logical, this rationale might not apply to all DIO2expressing tissue or cell types given that in a cell system in which conversion of T 4 to T 3 via DIO2 was monitored while cells were exposed to progressively higher T 4 levels, T 3 production was lower than the T 4 concentration in the medium only to a limited extent. 95 This change was followed by an inflection point at which further increases in T 4 concentration reduced DIO2 activity, and T 3 production fell abruptly; the level of T 4 at the inflection point depends on the cell type, presum ably because of differences in DIO2 ubiquitination. 95 This finding is supported by the observations that Dio2 activity in mice with brainspecific inactivation of Wsb-1 respond differently to T 4 administration across different brain areas. 17 For example, Wsb1 mediates Dio2 inacti vation in response to levothyroxine administration in brain areas such as the cerebral cortex and hippocampus, whereas in the cerebellum, Wsb1 does not mediate loss of Dio2 activity. Furthermore, levothyroxineinduced Dio2 inactivation is minimal (almost nonexistent), in the hypothalamus. 17 
Mood disorders and cognition
To what extent do the mechanisms mediated by iodothyro nine deiodinase that regulate thyroidhormone signalling underpin clinical phenotypes observed in patients with hypothyroidism? These patients have variable degrees of cognitive dysfunction, lethargy, poor motor coordination, memory impairment, depression and mood disorders. In addition, the efficacy of anti depressant agents among euthyroid individuals is potentiated when associated with the administration of thyroid hormone, either levo thyroxine or liothyronine. 103, 104 In some clinical studies, but not all, 105 a residual cognitive dysfunction exists in patients with hypothyroidism who are treated with levo thyroxine. 9, 53, 106, 107 Whether these residual symptoms are a consequence of low serum levels of T 3 , or a high T 4 to T 3 ratio, 108, 109 remains to be determined. In addition, whether combination therapy with levothyroxine and liothyronine can restore cognitive function is an interesting hypothesis that needs to be tested. Some evidence suggests that thyroid hormones act in the brain via serotonergic pathways, a system involved in the pathogenesis of affective disorders and response to psychotropic agents. 110 Arising from discrete brain stem nuclei, serotonin circuits project to cortical and sub cortical brain areas, including the prefrontal cortex, hippo campus and amygdala, which explains their influ ence on behaviours such as mood, sleep and appetite. 111 The use of MRI spectroscopy and PET has confirmed that thyroid hormones act in the human limbic system, with substantial differences observed in the posterior cingulate cortex and the inferior parietal lobe of hypothyroid versus hyperthyroid individuals. 112, 113 Considering that iodothyronine deiodinases modify thyroidhormone signalling in the rodent brain, 114 it seems logical to assume that the activity of these enzymes might affect mood and/or have a role in the vari ability of the response of patients with depression to T 3 . In animal models, Dio2 activity in the brain is increased by anti depressants of various classes, including selective sero tonin reuptake inhibitors. [115] [116] [117] In addition, hippo campal expression of Dio2 and Dio3 is increased in a mouse model that is resistant to stressinduced depression and after antidepressant treatment in mice. 108 However, a mouse with global inactivation of Dio2 exhibits only a mild motor phenotype and no behavioural pheno type. 61, 118 By contrast, a mouse model with global inacti vation of Dio3 exhibits brain hyperthyroidism, aggressive behaviour and indifference towards pups. 119 Furthermore, a negative corre lation exists between Dio3 expression and T 3 levels in the frontal cortex and hippocampus of a mouse model of depressive behaviour and cognitive deficits, which is partially restored by administration of levothyroxine. [120] [121] [122] The available clinical data are inconsistent for DIO2 and DIO3 but strong for DIO1, which is expressed at low levels in the human brain. 24, 79 A study of 1,447 indivi duals enrolled from the general population indicated that a polymorphism in DIO1, called C785T, is associated with the lifetime risk of depression in white female individuals in highrisk cohorts 123 and with the antidepressant effi cacy of T 3 in a trial of the selective serotonin reuptake inhibitor sertraline. 124 
Genetic risk and brain disease
A prevalent single nucleotide polymorphism in the DIO2 gene (which results in a single amino acid substi tution of Thr for Ala at position 92 in DIO2, thus called Thr92AlaD2) has been identified, 125 with estimates sug gesting that ~12-36% of individuals in the general popu lation are homozygous. This variant has been associated with metabolic derangements, including insulin resist ance 125, 126 and type 2 diabetes mellitus. 127 Furthermore, this polymorphism has been implicated in mental and psychological disorders, 45 such as mental retar dation, 128 bipolar disorder 129 and low IQ. 130 Conversely, Thr92AlaD2 might confer protection from recurrent depression. 131 The clinical relevance of Thr92AlaD2 was strengthened in a large clinical trial, in which the sub stitution was correlated with reduced wellbeing and a preference for levothyroxine plus liothyronine combi nation therapy versus levothyroxine monotherapy among carriers with hypothyroidism. 13 These findings have stimulated much intrigue in the field with most initial hypotheses focusing on a possible defect in thyroidhormone signalling. However, the single amino acid substitution associated with Thr92AlaD2 does not alter the enzyme kinetics of DIO2 when transiently expressed in cells 132, 133 and only indirect evidence suggests that the conversion of T 4 to T 3 via Thr92AlaD2 could be reduced in patients. 134, 135 Perhaps this observation is not unexpected given that the mutation lies not within the catalytic site but rather within the 18amino acid loop that controls suscepti bility to T 4 induced ubiquitination of DIO2. 31 The putative functional abnormality associ ated with expression of the variant protein was defined in studies performed in a human embryonic kidney cell line that had been engineered to stably express this mutation. The mutated protein has a longer halflife than the native form and is ectopically located in the Golgi apparatus. 35 This aberrant subcellular localization was associated with abnormal Golgi structure, such that cir cular (rather than linear or ribbonlike) stacks of Golgi membrane were observed. These cellular abnormalities resulted in alterations at the transcriptional level that were independent of DIO2mediated T 3 production given that the cell line studied does not express TRs 136 and that the observed gene expression pattern lacked typical indica tors of T 3 responsiveness. 114 Remarkably, when human cerebral cortex samples from patients harbouring the poly morphism were studied, overlap in the expression of 81 genes was found, which defines a molecular finger print associated with the Thr92AlaD2 variant across these human cell and brain models. 35 In addition, robust analysis of microarray data derived from human brain samples demonstrated a gene expres sion profile reminiscent of that of neurological diseases, particularly the gene expression profile associated with Huntington disease. 35 This finding implies that the Thr92AlaD2 polymorphism is a novel risk factor for neurodegenerative disease or impaired cognition, which might explain the neuropsychological impairment of some patients; however, further studies are needed before definite conclusions can be drawn. 35 In particular, eluci dating whether the high T 4 :T 3 ratio observed in patients with hypothyroidism who are treated with levothyrox ine 12,100 might perturb the cellular abnormalities associated with expression of the variant protein will be important. This relationship could explain the improved well being and preference for combination therapy recorded in a subgroup of patients, as no evidence of reduced thyroidhormone signalling in the samples was found (T 3 independent). 13 These findings represent a step towards determin ing the relationship between the cellular abnormalities associ ated with variant protein expression and the associ ated clinical phenotype. Future studies are needed to fully characterize the molecular basis for the clinical observa tions. Nevertheless, clinical trials among this subgroup of patients could be warranted to determine whether patients with hypothyroidism who carry the poly morphism would benefit from alternative therapeutic strategies. If it can be rigorously demonstrated that such patients derive benefit from combination therapy, then genotyping for Thr92AlaD2 could become a routine component of hypothyroidism management, thus bringing the concept of personalized medicine to the field.
Conclusions
Major advances have been made in the treatment of hypothyroidism over the past century; however, refined therapeutic regimens might still be needed to ensure that all patients can become asymptomatic and clinically euthyroid. Once heralded as the ultimate regulators of thyroidhormone availability and the key to levo thyrox ine treatment efficacy, iodothyronine deiodinases might actually underpin the inability to normalize serum levels of TSH and T 3 in patients receiving levothyroxine monotherapy and the insufficient symptomatic response experi enced by an appreciable proportion of patients with hypothyroidism. Future studies exploring the role of the iodothyronine deiodinases in hypothyroidism hold real promise for determining therapeutic regimens that can normalize systemic and tissuelevel parameters for all patients with hypothyroidism, including new approaches that might even be genotypedirected.
